OakChart

Cryo-Cell International Inc

CCELHealthcare·Medical Care Facilities·USA·Nano·AMEX·Nov 11 • 3:01 PM ET

5.01+0.14 (2.87%)
2026-11-11 21:12 CET
Market cap
39.27 USD m
Revenue, TTM
31.13 USD m
Net income, TTM
-1.95 USD m
Free cash flow, TTM
4.65 USD m
EPS diluted, TTM
-0.24
P/E
-
Compare

Price

CCEL against its 20, 50 and 200-day averages
2050200beatearnings
3.004.005.00344K687KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CCELclose 5.0120-day 4.8350-day 4.43200-day 3.745.0152w high

8.0% under the 52-week high of 5.45 on 29 Oct 2026. 52-week low 2.72 on 25 Mar 2026. Last 15 sessions, 27.2% high to low

Volume 0.09× normal · the line is the 50-bar volume average

Profile

CCEL
52-week range, 84% of the way up
2.725.45

Cryo-Cell International, Inc. is a cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. It operates through the following segments: Umbilical Cord Blood and Cord Tissue Stem Cell Service, PrepaCyte CB, and Public Cord Blood Banking. The Umbilical Cord Blood and Cord Tissue Stem Cell Service segment refers to cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use. The PrepaCyte CB segment focuses on the manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells. The Public Cord Blood Banking segment relates to the cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company was founded in 1989 and is headquartered in Oldsmar, FL.

Employees76
IPOApr 04, 1994
Beta0.45
ATR, 14d0.34
Rel volume0.09
Short float0.29%
Insider own47.86%
Inst own13.78%

Snapshot

6 groups

Valuation

Index-
Market Cap40.40M
Enterprise Value44.99M
Income-1.95M
Sales31.13M
Book/sh-2.03
Cash/sh0.52
Dividend Est.-
Dividend TTM-
Dividend Ex-DateMay 21, 2025
Dividend Gr. 3/5Y- -
Payout-
Employees76
IPOApr 04, 1994

Ratios

P/E-
Forward P/E-
PEG-
P/S1.30
P/B-
P/C9.55
P/FCF8.69
EV/EBITDA29.21
EV/Sales1.45
Quick Ratio0.82
Current Ratio0.86
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.24
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y1.33% 0.27%
EPS Y/Y TTM-314.41%
Sales Y/Y TTM-1.96%
EPS Q/Q69.72%
Sales Q/Q-0.02%
EarningsOct 09 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own47.86%
Insider Trans0.00%
Inst Own13.78%
Inst Trans1.86%
ROA-3.10%
ROE-
ROIC-
Gross Margin76.17%
Oper. Margin0.61%
Profit Margin-6.25%
SMA203.63%
SMA5013.16%
SMA20033.86%
Trades-

Technical

Shs Outstand8.06M
Shs Float4.20M
Short Float0.29%
Short Ratio0.51
Short Interest0.01M
52W High5.45 -7.99%
52W Low2.72 84.19%
Volatility4.33% 8.20%
ATR (14)0.34
RSI (14)57.17
Beta0.45
Rel Volume0.09
Avg Volume23.77K
Volume1,845

Performance

Perf Week-1.18%
Perf Month16.51%
Perf Quarter28.63%
Perf Half Y43.14%
Perf YTD45.64%
Perf Year24.01%
Perf 3Y-2.72%
Perf 5Y-51.35%
Perf 10Y44.48%
Recom1.00
Target Price8.50
Prev Close4.87
Price5.01
Change %2.87%

Peers

Mkt cap
TickerCompanyMkt cap
COOCooper Companies Inc11.98B
CELUCelularity Inc23.95M
NIVFNewGenIvf Group Ltd0.38M
BSEMBioStem Technologies Inc27.36M
MDXGMimedx Group Inc489.71M
IVFINVO Fertility Inc3.08M
LGVNLongeveron Inc10.36M
NTRANatera Inc46.09B
VCELVericel Corp3.00B
BRTXBioRestorative Therapies Inc2.10M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
TAYMANS JILL MVP Finance, CFOMay 28 '26Option Exercise3.107,50023,25052,896May 29 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 90

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-090.160-0.1607.82--
2026Q22026-07-150.0700.0000.0697.807.551
2026Q12026-04-140.010-0.0200.0067.687.701
2025Q42026-02-27-0.460-0.090-0.4747.907.701
2025Q32025-10-150.090-0.0300.0937.838.001
2025Q22025-07-150.040-0.0400.0447.908.001
2025Q12025-04-150.0300.0100.0357.977.901
2024Q42025-02-28-0.2300.020-0.2308.117.991
2024Q32024-10-150.1300.0300.1298.078.001
2024Q22024-07-150.0800.0500.0807.978.001
2024Q12024-04-150.070-0.0100.0677.857.901
2023Q42024-02-28-1.340-0.070-1.3507.847.901
2023Q32023-10-120.080-0.0500.0827.877.801
2023Q22023-07-140.030-0.0700.0277.777.801
2023Q12023-04-210.090-0.0300.0917.827.401
2022Q42023-02-280.130-0.0100.0997.807.261

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.270-0.27231.82-
2020FY0.450-0.44531.10-
2022FY0.3300.2600.32730.3429.84
2023FY-1.1400.180-1.14231.3031.40
2024FY0.0500.3800.04932.0031.95
2025FY-0.3000.110-0.30031.6031.50
2026FY-0.110--30.04
2027FY-0.020--28.41

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-07-161007.357.357.35
2026Q4S2026-04-151007.357.357.35
2026Q4S2026-03-021107.407.407.40
2026Q4S2025-12-311007.307.307.30
2026Q4S2025-11-111017.307.307.30
2026Q4S2025-11-101017.307.307.30
2026Q4S2025-11-091017.307.307.30
2026Q4S2025-11-081017.307.307.30
2026Q4S2025-11-071017.307.307.30
2026Q4S2025-11-061017.307.307.30
2026Q4S2025-11-051017.307.307.30
2026Q4S2025-11-041017.307.307.30
2026Q4S2025-11-031017.307.307.30
2026Q4S2025-11-021017.307.307.30

Estimate history

EPS, annual0.3-0.1150.2720.4450.2490.327-1.1420.049-0.301-0.2417
Period201720182019202020212022202320242025TTM
EPS, quarterly0.129-0.230.0350.0440.093-0.4740.0060.0690.158
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual25.38429.21831.81731.14828.88530.33731.34431.98631.56631.13
Period201720182019202020212022202320242025TTM
Sales, quarterly8.0678.0247.9697.9297.8257.8437.6837.7767.824
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual7.1047.8017.5117.5468.5578.5018.2878.0828.0558.063
Period201720182019202020212022202320242025MRQ
Shares, quarterly8.0628.0828.0828.0648.0558.0558.0558.0638.063
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue31.1331.5731.9931.3430.3428.8831.1531.8229.22
Cost of Goods Sold Incl. D&A7.428.138.439.579.919.829.8210.248.72
Gross Profit23.7123.4423.5521.7820.4219.0621.3221.5720.50
Selling, General and Administrative Excl. Other19.1618.6019.7618.2915.9714.6814.3214.9215.14
Research and Development0.300.381.241.170.380.050.020.030.09
Other Operating Expense4.364.360.003.740.001.161.282.330.00
Operating Income0.190.483.79-0.254.463.225.724.325.35
Interest Expense1.822.071.861.241.521.381.541.701.55
Unusual Expense0.300.81-0.8711.880.03-0.77-0.86-0.710.19
Net Income Before Taxes-1.91-2.342.80-13.363.322.615.043.393.62
Income Taxes0.040.092.40-3.840.550.531.411.104.47
Consolidated Net Income-1.95-2.430.40-9.522.772.083.622.29-0.85
Net Income From Continuing Operations-1.95-2.430.40-9.522.772.083.622.29-0.85
Net Income-1.95-2.430.40-9.522.772.083.622.29-0.85
EPS (Recurring)-0.22-0.23-0.03-0.140.330.180.370.21-0.10
EPS (Basic, Before Extraordinaries)-0.24-0.300.05-1.140.330.260.480.29-0.11
EPS (Diluted)-0.24-0.300.05-1.140.330.250.450.27-0.11
EBITDA1.541.854.811.466.274.556.364.725.67
Non-Operating Income (Expense)0.030.050.010.000.410.000.000.060.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.320.330.620.650.360.220.450.290.38
Price To Earnings Ratio----13.5149.5016.8526.44-
Price To Sales Ratio1.091.102.231.421.223.581.962.001.87
Gross Margin76.1774.2573.6469.4867.3365.9968.4667.8170.16
Operating Margin0.611.5311.85-0.7914.7011.1518.3713.5818.32
Net Margin-6.25-7.701.26-30.389.147.2111.647.20-2.93
Shares Outstanding8.068.068.088.298.508.567.557.517.80
Market Capitalization39.2739.2769.9044.3337.23105.6056.5956.7156.66

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue7.827.787.687.847.837.937.978.02
Cost of Goods Sold Incl. D&A1.801.861.841.921.992.052.181.83
Gross Profit6.035.925.845.935.845.885.796.19
Selling, General and Administrative Excl. Other3.834.725.085.533.944.394.746.32
Research and Development0.050.100.070.080.060.130.100.30
Other Operating Expense0.000.000.004.360.000.000.000.00
Operating Income2.191.200.77-3.971.901.491.06-0.12
Interest Expense0.440.440.460.480.540.550.490.75
Unusual Expense-0.07-0.070.240.200.190.380.03-0.02
Net Income Before Taxes1.830.830.07-4.631.190.580.53-0.84
Income Taxes0.550.270.02-0.810.440.220.251.02
Consolidated Net Income1.270.550.05-3.820.750.360.28-1.86
Net Income From Continuing Operations1.270.550.05-3.820.750.360.28-1.86
Net Income1.270.550.05-3.820.750.360.28-1.86
EPS (Recurring)0.150.060.03-0.460.110.080.04-0.23
EPS (Basic, Before Extraordinaries)0.160.070.01-0.470.090.040.04-0.23
EPS (Diluted)0.160.070.01-0.470.090.040.03-0.23
EBITDA2.531.541.11-3.642.251.841.400.22
Non-Operating Income (Expense)0.000.000.010.020.020.010.000.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.070.050.160.030.030.030.230.12
Price To Earnings Ratio-----409.60176.34-
Price To Sales Ratio1.090.870.881.101.201.302.022.19
Gross Margin77.0276.0776.0575.5574.6174.1972.6977.16
Operating Margin28.0415.409.96-50.5824.2918.8313.25-1.54
Net Margin16.247.130.61-48.679.584.493.55-23.20
Shares Outstanding8.068.068.068.068.068.068.088.08
Market Capitalization39.2727.1527.3934.6437.8741.3863.6969.90

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments3.303.500.981.728.3410.457.456.926.72
Short Term Receivables6.857.316.586.045.256.326.105.875.13
Inventories0.410.660.770.850.920.931.0816.040.31
Other Current Assets1.211.091.130.991.270.860.760.720.58
Total Current Assets11.7612.559.459.6115.7818.5615.3929.5412.74
Net Property, Plant & Equipment21.8522.7022.0314.214.151.941.851.490.88
Total Investments and Advances0.000.000.310.310.310.310.310.310.00
Intangible Assets2.802.862.933.403.503.123.193.280.23
Deferred Tax Assets23.6220.8020.4913.7412.0110.369.087.6610.04
Other Assets1.695.766.0123.6124.9111.9113.070.110.03
Total Assets61.7364.6861.2264.8960.6646.2042.8942.3923.91
Short Term Debt Incl. Current Port. of LT Debt2.914.121.612.722.213.383.103.102.00
Accounts Payable2.871.883.171.611.490.961.371.261.93
Income Tax Payable0.001.421.430.340.000.960.180.320.36
Other Current Liabilities14.0114.1814.6514.8117.3711.1210.7810.749.65
Total Current Liabilities19.7921.6020.8619.4821.0716.4115.4315.4313.94
Long Term Debt8.648.829.288.890.612.865.869.845.30
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities51.9047.4842.1138.0434.7929.5928.5526.0317.18
Total Liabilities80.3377.8972.2566.4156.4848.8749.8451.3036.41
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-18.61-13.22-11.03-1.524.18-2.67-6.95-8.91-12.50
Total Shareholders Equity-18.61-13.22-11.03-1.524.18-2.67-6.95-8.91-12.50
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-18.61-13.22-11.03-1.524.18-2.67-6.95-8.91-12.50
Total Liabilities & Stockholders Equity61.7364.6861.2264.8960.6646.2042.8942.3923.91
Book Value Per Share-2.31-1.64-1.33-0.180.49-0.35-0.93-1.14-1.76
Tangible Book Value Per Share-2.66-1.99-1.68-0.580.08-0.77-1.35-1.56-1.79
Full-Time Employees768288889398979281
Price to Book Ratio-2.40-7.31-4.02-24.3725.32-21.23-8.46-6.41-4.58
Return on Assets-3.840.64-15.104.413.908.145.37-2.5810.66
Return on Equity---208.38274.30----
Return on Invested Capital---37.6143.451,814.92--91.40-
Quick Ratio0.570.550.420.450.711.070.930.870.89
Current Ratio0.590.580.450.490.751.131.001.910.91

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-1.95-2.430.40-9.522.772.083.622.29-0.85
Depreciation1.351.371.021.711.811.330.640.400.32
Other Funds (Non Cash)6.056.521.2017.501.471.311.732.871.06
Funds from Operations2.642.642.312.934.323.074.714.042.90
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.282.843.705.994.254.863.762.282.43
Cash from Operating Activities4.925.486.018.928.577.938.476.325.33
Capital Expenditures-0.27-0.23-2.40-6.84-12.17-6.95-0.45-0.66-0.65
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.120.000.001.870.000.000.00-
Purchase or Sale of Investments-0.15-0.86-1.27-0.510.020.000.81-0.03-0.14
Purchase of Investments-1.39-3.65-2.89-1.08-1.140.000.00-0.03-0.14
Sale Or Maturity of Investments1.242.791.620.581.160.000.81--
Other Uses0.000.00-1.20-0.80-5.000.000.000.00-10.50
Other Sources0.000.000.000.000.000.000.000.00-
Cash from Investing Activities-0.42-0.98-4.88-8.14-15.28-6.950.36-0.69-11.28
Cash Dividends Paid0.00-3.23-2.020.00-7.670.000.000.000.00
Change in Capital Stock0.02-0.15-1.35-0.80-1.271.030.04-0.990.17
Repurchase of Common Pref Stock0.00-0.17-1.42-0.80-1.82-0.250.00-0.990.00
Sale of Common Pref Stock0.020.020.080.000.551.280.040.010.17
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-3.37-1.372.16-1.219.09-4.10-3.10-4.105.54
Change in Long Term Debt-0.17-0.15-0.14-0.166.82-4.10-3.10-4.105.54
Issuance of Long Term Debt0.000.000.000.008.760.000.000.008.83
Reduction of Long Term Debt-0.17-0.15-0.14-0.16-1.95-4.10-3.10-4.10-3.29
Net Financing Active Other Cash Flow0.000.000.23-0.070.000.00-1.95-0.040.00
Other Financing Activities Uses0.000.000.00-0.070.000.00-1.95-0.040.00
Cash from Financing Activities-3.34-4.75-0.98-2.070.15-3.07-5.00-5.135.71
Net Change in Cash1.16-0.240.15-1.30-6.56-2.103.820.50-0.24
Free Cash Flow4.655.253.612.08-3.606.098.375.664.89
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow7.2817.2044.8721.45-16.997.3011.2211.18
Deferred Taxes & Investment Tax Credit--2.82-0.31-6.75-1.73-1.65-1.28-1.522.38

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments4.233.162.903.303.224.43
Short Term Receivables6.836.916.826.856.836.93
Inventories0.530.310.360.410.660.68
Other Current Assets1.580.921.001.210.961.01
Total Current Assets13.1711.3011.0811.7611.6713.05
Net Property, Plant & Equipment21.0721.2921.5921.8522.1122.01
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets2.772.782.792.802.822.83
Deferred Tax Assets23.6223.6223.6223.6220.8020.80
Other Assets1.671.711.801.695.775.74
Total Assets62.3060.7160.8861.7363.1764.44
Short Term Debt Incl. Current Port. of LT Debt0.630.622.222.913.817.26
Accounts Payable2.422.853.302.872.612.24
Income Tax Payable---0.00--
Other Current Liabilities12.2812.4712.2414.0112.0312.25
Total Current Liabilities15.3315.9317.7619.7918.4521.75
Long Term Debt8.198.348.508.648.788.50
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities55.1754.1953.0351.9050.7649.74
Total Liabilities78.7078.4679.2980.3378.0080.00
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-16.39-17.76-18.40-18.61-14.83-15.56
Total Shareholders Equity-16.39-17.76-18.40-18.61-14.83-15.56
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-16.39-17.76-18.40-18.61-14.83-15.56
Total Liabilities & Stockholders Equity62.3060.7160.8861.7363.1764.44
Book Value Per Share-2.03-2.20-2.28-2.31-1.84-1.93
Tangible Book Value Per Share-2.38-2.55-2.63-2.66-2.19-2.28
Full-Time Employees---76--
Price to Book Ratio-2.40-1.48-1.47-2.34-2.44-2.82
Return on Assets-3.10-3.94-4.26-3.84-0.75-0.27
Quick Ratio0.820.690.600.570.600.57
Current Ratio0.860.710.620.590.630.60

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income1.270.550.05-3.820.750.36
Depreciation0.330.340.340.330.350.34
Other Funds (Non Cash)0.420.320.624.700.650.57
Funds from Operations2.021.221.01-1.611.751.27
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.880.63-0.352.890.78-0.56
Cash from Operating Activities1.141.850.651.282.540.71
Capital Expenditures-0.10-0.03-0.07-0.07-0.04-0.06
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.12
Purchase or Sale of Investments-0.080.070.09-0.221.14-1.56
Purchase of Investments-0.24-0.15-0.51-0.49-0.59-1.97
Sale Or Maturity of Investments0.160.220.590.271.730.42
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.180.040.02-0.291.10-1.50
Cash Dividends Paid0.000.000.000.000.00-1.21
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.020.000.00-0.06-0.09
Repurchase of Common Pref Stock0.000.000.000.00-0.08-0.09
Sale of Common Pref Stock0.000.020.000.000.020.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.04-1.65-0.74-0.94-3.462.01
Change in Long Term Debt-0.04-0.05-0.04-0.04-0.04-0.04
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.04-0.05-0.04-0.04-0.04-0.04
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.04-1.62-0.74-0.94-3.510.71
Net Change in Cash0.920.26-0.070.050.13-0.09
Free Cash Flow1.041.810.581.212.500.64
Price to Free Cash Flow7.284.447.3417.1740.7460.73

Revenue breakdown

Processing And Storage Fees2024: 31.55M 2025: 31.38M
Product2024: 67.88K 2025: 54.10K
Public Banking2024: 366.67K 2025: 129.51K
United States2024: 31.99M 2025: 31.57M
Prepacytecb2024: 67.88K 2025: 54.10K
Public Cord Blood Banking2024: 366.67K 2025: 129.51K
Umbilical Cord Blood And Cord Tissue Stem Cell Service2024: 31.55M 2025: 31.38M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.29%0.0M4.2M24.23K
2026-10-150.17%0.0M4.2M24.66K
2026-09-300.15%0.0M4.2M24.06K
2026-09-150.22%0.0M4.2M24.40K
2026-08-310.13%0.0M4.2M22.11K
2026-08-140.30%0.0M4.2M20.48K
2026-07-310.21%0.0M4.2M9.03K
2026-07-150.22%0.0M4.2M9.07K
2026-06-300.15%0.0M4.2M8.52K
2026-06-150.24%0.0M4.2M11.06K
2026-05-290.35%0.0M4.2M12.05K
2026-05-150.23%0.0M4.2M11.73K
2026-04-300.17%0.0M4.2M13.94K
2026-04-150.19%0.0M4.2M13.67K
2026-03-310.29%0.0M3.8M16.04K
2026-03-130.15%0.0M3.8M12.65K
2026-02-270.23%0.0M3.8M11.49K
2026-02-130.25%0.0M3.8M10.95K
2026-01-300.19%0.0M3.8M8.45K
2026-01-150.18%0.0M3.8M7.76K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-284Statement of changes in beneficial ownership of securities2026-10-27SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-27SEC
2026-10-288-KCurrent report2026-10-27SEC
2026-10-13DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-27SEC
2026-10-13ARSAnnual report to security holders. 2025-11-30SEC
2026-10-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-08-31SEC
2026-09-148-KCurrent report2026-09-10SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-07-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-05-31SEC
2026-07-07SCHEDULE 13D/ASEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-088-KCurrent report2026-05-06SEC
2026-04-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-02-28SEC
2026-03-25SCHEDULE 13DSEC
2026-03-128-KCurrent report2026-03-09SEC
2026-02-2710-KAnnual report pursuant to Section 13 or 15(d)2025-11-30SEC
2026-01-094Statement of changes in beneficial ownership of securities2026-01-07SEC
2026-01-094Statement of changes in beneficial ownership of securities2026-01-07SEC
2026-01-094Statement of changes in beneficial ownership of securities2026-01-07SEC
2026-01-094Statement of changes in beneficial ownership of securities2026-01-07SEC
2025-11-244Statement of changes in beneficial ownership of securities2025-11-20SEC
2025-11-194Statement of changes in beneficial ownership of securities2025-11-17SEC
2025-11-124Statement of changes in beneficial ownership of securities2025-11-10SEC
2025-11-128-KCurrent report2025-11-12SEC
2025-11-044Statement of changes in beneficial ownership of securities2025-10-31SEC
2025-10-234Statement of changes in beneficial ownership of securities2025-10-21SEC
2025-10-234Statement of changes in beneficial ownership of securities2025-10-21SEC
2025-10-238-KCurrent report2025-10-18SEC
2025-10-1510-QQuarterly report pursuant to Section 13 or 15(d)2025-08-31SEC
2025-09-26DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-10-21SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
SFI Advisors, LLC2.05%
VANGUARD CAPITAL MANAGEMENT LLC2.05%
MassMutual Private Wealth & Trust, FSB1.38%
GEODE CAPITAL MANAGEMENT, LLC0.57%
VANGUARD FIDUCIARY TRUST CO0.29%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.17%
BlackRock, Inc.0.08%
BARCLAYS PLC0.06%
OSAIC HOLDINGS, INC.0.03%
MORGAN STANLEY0.01%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.18%
VANGUARD EXTENDED MARKET INDEX FUND0.56%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.35%
Fidelity Extended Market Index Fund0.29%
Fidelity Total Market Index Fund0.11%
Fidelity Series Total Market Index Fund0.09%
iShares Micro-Cap ETF0.09%
1290 VT Micro Cap Portfolio0.01%

OakChart. CCEL. Cached 15 minutes.

Some panels did not load: ratings.